佐剂重组带状疱疹疫苗安全性:两项大型III期随机试验汇总分析
基于ZOE-50和ZOE-70两项III期随机试验的汇总分析,纳入14645名RZV接种者和14660名安慰剂接种者,评估佐剂重组带状疱疹疫苗(RZV)的安全性。结果显示RZV组非征集性不良事件报告率高于安慰剂组(50.5% vs 32.0%),但严重不良事件、致死性不良事件及潜在免疫介导疾病在两组间均衡,未发现安全性问题。
要点
- RZV组非征集性不良事件报告率高于安慰剂组,差异主要由短暂的注射部位和征集性全身反应驱动。
- 严重不良事件、致死性不良事件及潜在免疫介导疾病的发生率在RZV组与安慰剂组间均衡。
- 除预期的局部和全身症状外,安全性结果在年龄、性别或种族亚组中与安慰剂组相当。
核心结论
- 未发现安全性问题,支持RZV具有良好的获益-风险特征。
研究设计与样本
- 汇总ZOE-50(NCT01165177)和ZOE-70(NCT01165229)两项III期随机试验的安全性数据,分析总接种队列包括至少接种一剂RZV或安慰剂的参与者。
主要发现
- RZV组非征集性不良事件报告率为50.5%,安慰剂组为32.0%,差异主要由接种后第一周内短暂的注射部位和征集性全身反应驱动。
- 总体严重不良事件发生率RZV组10.1%、安慰剂组10.4%;致死性不良事件RZV组4.3%、安慰剂组4.6%;潜在免疫介导疾病RZV组1.2%、安慰剂组1.4%,两组间均衡。
- 潜在免疫介导疾病可能的加重罕见且两组相似。
关键数值与推荐
- 征集性不良事件收集至每次接种后7天,非征集性不良事件收集至每次接种后30天,严重不良事件收集至末次接种后12个月。
临床怎么用
- 接种RZV后可能出现短暂的注射部位和全身反应,但严重不良事件风险与安慰剂相当,支持在≥50岁和≥70岁人群中接种。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies. METHODS: Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30 days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12 months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period. RESULTS: Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race. CONCLUSIONS: No safety concerns arose, supporting the favorable benefit-risk profile of RZV.
引用
- López-Fauqued M, Campora L, Delannois F, et al. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. Vaccine. 2019. PMID: 30935742. doi:10.1016/j.vaccine.2019.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。